Basit öğe kaydını göster

dc.contributor.authorGedikli, Omer
dc.contributor.authorSinan, Umit Yasar
dc.contributor.authorBEŞLİ, FEYZULLAH
dc.contributor.authorTok, Ozge Ozden
dc.contributor.authorCakmak, Huseyin Altug
dc.contributor.authorAltay, Servet
dc.contributor.authorYildirimturk, Ozlem
dc.contributor.authorAskin, Lutfu
dc.date.accessioned2021-03-05T15:21:40Z
dc.date.available2021-03-05T15:21:40Z
dc.date.issued2017
dc.identifier.citationAltay S., Yildirimturk O., Cakmak H. A. , Askin L., Sinan U. Y. , BEŞLİ F., Gedikli O., Tok O. O. , "New oral anticoagulants-TURKey (NOAC-TURK): Multicenter cross-sectional study", ANATOLIAN JOURNAL OF CARDIOLOGY, cilt.17, ss.353-361, 2017
dc.identifier.issn2149-2263
dc.identifier.othervv_1032021
dc.identifier.otherav_bb8760bd-5dc3-47bf-92c0-5f0a8ff78391
dc.identifier.urihttp://hdl.handle.net/20.500.12627/124696
dc.identifier.urihttps://doi.org/10.14744/anatoljcardiol.2016.7472
dc.description.abstractObjective: New oral anticoagulants (NOACs) are increasingly used both for prevention of stroke in non-valvular atrial fibrillation (NVAF) and the treatment of venous thromboembolism (VTE). In this study, we aimed to evaluate the current patterns of NOACs treatment in Turkey. Moreover, demographic and clinical parameters and bleeding and/or embolic events under NOACs treatment were analyzed.
dc.language.isoeng
dc.subjectKardiyoloji
dc.subjectDahili Tıp Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectCARDIAC ve CARDIOVASCULAR SİSTEMLER
dc.titleNew oral anticoagulants-TURKey (NOAC-TURK): Multicenter cross-sectional study
dc.typeMakale
dc.relation.journalANATOLIAN JOURNAL OF CARDIOLOGY
dc.contributor.department, ,
dc.identifier.volume17
dc.identifier.issue5
dc.identifier.startpage353
dc.identifier.endpage361
dc.contributor.firstauthorID242759


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster